What Is CJC-1295 - NO DAC 2MG?
CJC-1295 no DAC is a man-made analog of growth hormone secretagogue (GHS) and growth hormone-releasing hormone (GHRH). It is composed of 29 amino acids and is available either in the form of CJC-1295 no DAC or CJC with DAC. DAC (drug affinity complex) is a molecule attached to CJC-1295, responsible for extending its half-life.
As a GHS, it has been shown to enhance muscle growth and performance, thus prohibited by the World Anti-Doping Agency (WADA). Limited research has been conducted to explore its therapeutic potential. It has not been approved by the FDA yet and is classified as an investigational drug. At Pinnacle Peptides, CJC-195 no DAC for sale is exclusively available for research and educational purposes.
Structure Of CJC-1295 - NO DAC 2MG
From Pubchem
Synonyms: CJC1295 Without DAC
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.9 g/mol Sequence: YADAXFXQSYRKVLAQLSARKLLQDXLSR
PubChem CID: 91976842
History
CJC-1295 was first developed in the mid-2000s by a Canadian company named ConjuChem Technologies. It was designed as a substitute for short-acting injectable growth hormone. It was investigated under phase II clinical trials for the treatment of lipodystrophy, but the death of one participant put the trial to a halt. Researchers involved in the trial explained that the death might occurred because the patient had asymptomatic coronary artery disease with rupture and occlusion. Nonetheless, the research was terminated for precautionary measures.
Mechanism Of CJC-1295 - NO DAC 2MG
CJC-1295 binds to receptors in the pituitary gland and stimulates the release of growth hormone and insulin-like growth factor-1 (IGF-1). It mimics the actions of sermorelin, which increases GH levels and acts on growth hormone-releasing hormone (GHRH) receptors.
Pre-Clinical/Clinical Research
CJC-1295, an analog of GHRH (Growth Hormone-Releasing Hormone), stimulates the release of growth hormone in a pulsatile fashion and elevates IGF-1 levels [1]. In a study involving mice with the GHRH gene ablation, CJC-1295 was administered at intervals of 24, 48, and 72 hours over several weeks. Results showed that mice receiving daily doses maintained normal body weight and length, whereas those treated every 48 and 72 hours experienced increased body weight and length. Further, an increased expression of GH mRNA was observed [2].
CJC-1295, with its extended half-life, provides a prolonged duration of action. A study was conducted to evaluate the pharmacokinetics, pharmacodynamics, and safety profile of CJC-1295. The findings indicated that subcutaneous administration of CJC-1295 led to a significant increase in growth hormone levels (2-3-fold for 6 days) and IGF-1 levels (1.5-3-fold for 9-11 days). Moreover, it was established that the tested doses (30 or 60 µg/kg) were well-tolerated [3]. Although not FDA-approved, research shows that its use has been found in females for youthful appearance [4].
Summary
CJC-1295 no DAC is a synthetic analog of GHS and GHRH. It has been shown to treat disorders related to growth hormone deficiency. It is prohibited by the WADA for its potential to enhance athletic performance. This synthetic peptide has not been studied extensively as is classified as an investigational drug. We don’t encourage its unwarranted use and offer CJC-1295 no DAC purchase for research purposes. Only buy CJC-195 no DAC if you are an authorized researcher.
References
- Ionescu, M. and L.A. Frohman, Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 2006. 91(12): p. 4792-7.
- Alba, M., et al., Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab, 2006. 291(6): p. E1290-4.
- Teichman, S.L., et al., Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. The Journal of Clinical Endocrinology & Metabolism, 2006. 91(3): p. 799-805.
- Van Hout, M.C. and E. Hearne, Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse, 2016. 51(1): p. 73-84.
Certificate of Analysis (COA)
High Performance Liquid Chromatography (HPLC)
Mass Spectrometry (MS)
-
Wonderful!Wonderful!.. Love everything about this site.
Posted on
-
Very professionalVery professional. Thanks guys.
Posted on
-
TOP!The quality is TOP! Will buy again.
Posted on
-
Great qualityDependable. I will continue to purchase.
Posted on
-
Great supplierRecommend them for sure
Posted on
-
Wonderful productGreat prices, fast delivery, wonderful product.
Posted on
-
Will recommendExtremely nice customer service and helpful. I will highly recommend it to my friends.Great product.
Posted on
-
ProfessionalVery happy with the product and the people. Professional !!
Posted on
-
WonderfulWonderful, love these products..
Posted on
-
Fast professional serviceFast professional service
Posted on